Neosporin®
Neomycin Sulfate, Polymyxin B Sulfate, Gramicidin · ophthalmic solution
Antibiotic
Approved uses
Superficial bacterial infection of the external eye and adnexa: conjunctivitis, keratitis, keratoconjunctivitis, blepharitis, blepharoconjunctivitis
1 or 2 drops into the affected eye every 4 hours for 7 to 10 days; up to 2 drops every hour in severe infection
Contraindications
Hypersensitivity to any component of the product.
Ophthalmic solution, 10 mL plastic squeeze bottle with controlled drop tip, neomycin sulfate equivalent to 1.75 mg base per mL, polymyxin B sulfate 10,000 units per mL, gramicidin 0.025 mg per mL
Three bactericidal agents with overlapping spectra: neomycin, an aminoglycoside, inhibits protein synthesis by binding with ribosomal RNA and causing misreading of the bacterial genetic code; polymyxin B interacts with membrane phospholipids to increase permeability in gram-negatives; gramicidin forms channels through the lipid bilayer that make the membrane permeable to inorganic cations in gram-positives. Together they are considered active against Staphylococcus aureus, streptococci including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter species, Neisseria species, and Pseudomonas aeruginosa, but the product does not provide adequate coverage against Serratia marcescens.
Warnings & Precautions
- Not for injection into the eye: Never introduce this product directly into the anterior chamber of the eye or inject it subconjunctivally.
- Cutaneous sensitization: Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization, usually shown as itching, reddening, and edema of the conjunctiva and eyelid; symptoms usually subside quickly after withdrawal, and products containing these ingredients should be avoided thereafter. In a retrospective analysis of North American Contact Dermatitis Group data from 2005 to 2016, 28,640 patients underwent patch testing and neomycin was the third most frequent allergen (US, 11.7%).
- Failure to heal: A sensitization reaction may manifest simply as failure to heal, so periodic examination for these signs is advisable during long-term use, and the patient should be told to discontinue the product if they are observed.
- Allergic cross-reactions: Sensitization may preclude later use of kanamycin, paromomycin, streptomycin, and possibly gentamicin.
- Superinfection and resistance: Prolonged use may allow overgrowth of nonsusceptible organisms including fungi, and appropriate measures should be initiated if superinfection occurs; bacterial resistance may also develop.
- Aggravated discharge, inflammation or pain: If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use and consult a physician; the patient should also stop use and consult a physician if the condition persists or gets worse, or if a rash or other allergic reaction develops.
- Bacterial keratitis: Bacterial keratitis has been reported after inadvertent patient contamination of multiple-dose topical ophthalmic containers, most of those patients having concurrent corneal disease or a disrupted ocular epithelial surface.
- Serious damage to the eye and loss of vision: Avoid letting the tip of the dispensing container contact the eye, eyelid, fingers, or any other surface; ocular products handled improperly can become contaminated by common bacteria, and serious damage to the eye and subsequent loss of vision may result from using contaminated products. Use of this product by more than one person may spread infection.
- Thimerosal preservative: The vehicle contains thimerosal 0.001% and alcohol (0.5%), and in two German cohorts of patients with periorbital dermatitis (88 and 2035 patients), thimerosal (10%) was among the most relevant allergens inducing periorbital eczema.
Common Side Effects
Reactions occurring most often are allergic reactions, including itching, swelling, and conjunctival erythema; the exact incidence is not known. Local irritation on instillation has also been reported. More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely.
Pregnancy: Adequate animal reproduction studies have not been conducted with neomycin, polymyxin B, or gramicidin, and whether the product can cause fetal harm or affect reproductive capacity is unknown, so give only if clearly needed.
Lactation: Excretion in human milk is unknown, so caution is warranted in a nursing woman.
Safety and effectiveness in pediatric patients have not been established.